-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV-2-IN-15
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1580-42-3.gif)
| Category | SARS-CoV |
| CAS | 1580-42-3 |
| Description | SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally. |
Product Information
| Synonyms | 5-chloro-2-hydroxy-N-[3-(trifluoromethyl)phenyl]benzamide|1580-42-3|SARS-CoV-2-IN-15|CHEMBL589733|MMV665807|SJ000010289|SCHEMBL330629|ZINC263553|BAA58042|BDBM50430176|NSC766528|AKOS001603002|NSC-766528|HY-144772|CS-0434460|SR-01000421155|SR-01000421155-1|Z1766231769|N-(3-(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide|Benzamide, 5-chloro-2-hydroxy-N-[3-(trifluoromethyl)phenyl]-|benzamide,5-chloro-2-hydroxy-n-[3-(trifluoromethyl)phenyl]- |
| Molecular Weight | 315.67 |
| Molecular Formula | C14H9ClF3NO2 |
| Canonical SMILES | C1=CC(=CC(=C1)NC(=O)C2=C(C=CC(=C2)Cl)O)C(F)(F)F |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 378 |
| Exact Mass | 315.0273907 |
| Target | SARS-CoV |
| XLogP3-AA | 4.5 |
